BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 8223747)

  • 1. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
    Kochs M; Eggeling T; Hombach V
    Eur Heart J; 1993 Sep; 14 Suppl E():107-19. PubMed ID: 8223747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
    Singh BN
    Am J Cardiol; 1990 Sep; 66(9):9C-20C. PubMed ID: 1699400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amiodarone: clinical trials.
    Naccarelli GV; Wolbrette DL; Patel HM; Luck JC
    Curr Opin Cardiol; 2000 Jan; 15(1):64-72. PubMed ID: 10666663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can antiarrhythmic drugs survive survival trials?
    Pratt CM; Waldo AL; Camm AJ
    Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
    Stevenson WG; Ridker PM
    JAMA; 1996 Aug; 276(6):481-5. PubMed ID: 8691557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmic risk stratification of post-myocardial infarction patients.
    Naccarella F; Lepera G; Rolli A
    Curr Opin Cardiol; 2000 Jan; 15(1):1-6. PubMed ID: 10666655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
    Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
    Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-arrhythmic therapy of ventricular tachyarrhythmias and sudden cardiac death after acute myocardial infarction.
    Schweitzer P
    Vnitr Lek; 2006 Dec; 52(12):1185-9. PubMed ID: 17299912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sudden cardiac death--possibilities and limits of drug therapy].
    Manz M; Lüderitz B
    Z Kardiol; 1992 May; 81(5):237-45. PubMed ID: 1621403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
    Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
    Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
    Singh BN
    Heart Fail Rev; 2002 Jul; 7(3):285-300. PubMed ID: 12215733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis and risk stratification after myocardial infarction.
    Breithardt G; Borggrefe M; Fetsch T; Böcker D; Mäkijärvi M; Reinhardt L
    Eur Heart J; 1995 Aug; 16 Suppl G():10-9. PubMed ID: 8595793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
    Anderson KP; Bigger JT; Freedman RA
    Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
    Fogoros RN
    Control Clin Trials; 1996 Jun; 17(3 Suppl):37S-46S. PubMed ID: 8877266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ventricular tachyarrhythmia. Drug therapy and evaluation of success].
    Seipel L; Kühlkamp V
    Z Kardiol; 1993; 82 Suppl 5():155-61. PubMed ID: 8154157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.